European Union Negotiates with Vaccine Producers

European Union Negotiates with Vaccine Producers

Author: European Commission

The European Commission has concluded exploratory talks with Moderna to purchase a potential vaccine against COVID-19. Moderna is the fifth company with which the Commission has concluded talks, following Sanofi-GSK on 31 July, Johnson & Johnson on 13 August, CureVac on 18 August, in addition to the signature of an Advance Purchase Agreement with AstraZeneca on 14 August.

The envisaged contract with Moderna would provide for the possibility for all EU Member States to purchase the vaccine, as well as to donate to lower- and middle-income countries or re-direct to European countries. It is anticipated that the Commission will have a contractual framework in place for the initial purchase of 80 million doses on behalf of all EU Member States, plus an option to purchase up to a further 80 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. The Commission pursues intensive discussions with other vaccine manufacturers. They plan to invest in companies using diverse technologies, to increase Europe’s chances to have vaccines that are safe and effective.


 

 

 

 

Leave a Reply

Your email address will not be published.